Identification of the Risk Factors for Complex-Multiple Long-term Conditions (C-MLTC): A Scoping Review
=======================================================================================================

* C Heneghan
* I Onakpoya
* J Brassey
* JP Sheppard
* A Tsiachristas
* K Bhui
* R Perera
* A Bennett

## Abstract

**Background** Complex multiple long-term conditions (C-MLTC) is commonly defined as the presence of four or more long-term conditions, and its prevalence is projected to increase significantly over the next decade.

**Methods** We undertook a scoping review of the literature to identify the available evidence on the risk factors for C-MLTC as well as to map out the potential clusters. We focussed on a subset of 18 chronic conditions because they include the most commonly reported and prevalent conditions in the general population. We searched NICE Clinical Knowledge Summaries (CKS) and PubMed, Register of Controlled Trials (Cochrane CENTRAL), Google Scholar and TRIP database for guidelines and reports.

**Results** We found 53 risk factors associated with 18 long-term conditions. Sixteen of these are linked to C-MLTC, with 11 being modifiable. Although we reviewed 35 systematic reviews, inconsistent reporting made it difficult to quantify the risk factors and conditions associated with C-MLTC. Diabetes mellitus is a risk factor for most other conditions (10), followed by coronary heart disease, hypertension, and chronic kidney disease (each associated with 8 long-term conditions). Additionally, depression and anxiety are commonly associated with other long-term conditions, with 14 and 17 conditions, respectively.

**Conclusion** Several risks and conditions contribute to the development of multimorbidity. Anxiety and depression are nearly associated with all long-term conditions. Reporting problems within the existing evidence and a lack of clear definitions prevent adequate quantification of the risks associated with C-MLTC.

## Background

One in four adults in England has Multiple Long-Term Conditions (MLTC), which is the co-occurrence of two or more diseases in the same individual, each of which must be a non-communicable disease (NCD). 1 NCDs account for roughly 70% of all deaths globally 2 and are more common with ageing, affecting two-thirds of the elderly. 3

Multimorbidity is commonly understood to be the coexistence of multiple long-term conditions in an individual. However, its study is limited because the predominant research approach has been to study single diseases or through the lens of comorbidity. The concept of single disease characterisation dates back to Thomas Sydenham (Diseases 1624-89), who differentiated “Acute diseases meaning those of which God is the author, chronic meaning those that originate in ourselves”. 4 In 1957, the concept of “risk factors’’ in coronary heart disease (CHD) was first coined by the Framingham Heart Study (FHS). In 1970, Feinstein coined the term comorbidity, 5 providing definitions that Indicate two or more medical conditions existing simultaneously regardless of their causal relationship. Complex-MLTC (C-MLTC) is commonly defined as the presence of four or more long-term conditions; this is projected to increase to 17% of the adult population by 2035, partly due to the ageing population. The evidence shows that Complex-MLTC decreases the quality of life and increases morbidity and mortality. 6 7

Current management tends to focus on treating individual conditions, and single-disease guidelines often do not consider patients with multimorbidity. 8 Furthermore, the transition from single conditions to C-MLTC is poorly understood. For example, there is a lack of understanding of what increases the risk or speeds up the transition to C-MLTC, and there is limited evidence on the life course for progression to Complex-MLTC and whether specific interventions can decrease the risk. 9 There is a lack of evidence about whether overdiagnosis and polypharmacy increase the risk of or progression to C-MLTC, and there are uncertainties about the effectiveness of interventions generally due to a paucity of randomised controlled trials. 10

Complex-MLTC may occur due to different combinations of chronic conditions, and it is unclear how the health and economic burden to patients, their carers and care systems is distributed across the different clusters of disease that may occur. 11 Research is emerging to identify which conditions cluster together, how the burden of complex-MLTC relates to health and ageing, what risk factors influence the development of C-MLTC, and which chronic conditions influence the burden of disease. As an example, a recent retrospective longitudinal (panel) study identified multimorbidity clusters with the highest primary care demand by consultation type and ethnicity. 12

We undertook a scoping review of the literature to identify the available evidence on the risk factors for C-MLTC and to map out potential clusters of C-MLTC.

### Objectives

1.  To identify the risk factors and conditions associated with C-MLTC.

2.  To identify studies that report on the aetiology, development, and risk factors for C-MLTC.

## Methods

### Inclusion Criteria

We focussed the review and outputs on a subset of 18 chronic conditions affecting the cardiovascular, renal, musculoskeletal and respiratory systems, mental health conditions and cancer. The 18 conditions are Stroke/TIA, Coronary heart disease (CHD), Atrial Fibrillation (AF), Heart Failure (HF), Hypertension, Peripheral Arterial Disease (PAD), Diabetes Mellitus Asthma, Chronic Obstructive Pulmonary Disease (COPD), Dementia, Parkinson’s Disease; Depression; Anxiety; Serious Mental Illnesses (Bipolar Disorder and Schizophrenia); Cancer excluding non-melanoma skin cancers; Chronic Kidney Disease (CKD); Osteoporosis; Rheumatoid Arthritis (RA).

We focussed on this subset of 18 chronic conditions because they include the most commonly reported and prevalent in the general population, in mid-life (45-64 years) and in early old age (64-85 years). 13 14 15 To address question 1, we identified risk factors and conditions associated with C-MLTC; we cross-tabulated LTC risk factors by the individual condition based on NICE Clinical Knowledge Summaries (CKS) ([https://cks.nice.org.uk/](https://cks.nice.org.uk/)), tabulating the risk factors for each of the 18 conditions and the relationship of the 18 conditions as risk factors. To address question 2, we identified studies that reported on the aetiology, development and risk factors for C-MLTC and generated the following PECO criteria:

P: Individuals with one of the 18 long-term conditions

E: Risk factors (identified in Question 1)

C: No risk factor

O: Increase in the risk of C-MLTC

We then searched for *systematic reviews* that included MLTC and reported as an outcome of the development of MLTC across the 18 conditions that fulfilled the PECO criteria above. In addition, for a study to be eligible, study participants had to be 18 years or older; the modifiable risk factor must have predated the outcome of one of the 18 specified diseases in adulthood. We included systematic reviews containing studies meeting our eligibility criteria. Where applicable, we included guidelines or guideline reports from the grey literature. We included studies in English.

### Search

We searched the following electronic databases: PubMed, Register of Controlled Trials (Cochrane CENTRAL), Google Scholar and TRIP database for guidelines and reports. The search was conducted in each database from inception until 31 May 2023. The search terms were developed iteratively using the 18 conditions as the starting point of their search. Search terms used included *comorbidity/ or multimorbidity/

(comorbid* or co-morbid*), (multi-morbid* or multimorbid* or multicomorbid* or multi-comorbid*), ((multiple or multisystem* or multi-system*) adj2 (condition? or disease? or disorder? or patholog* or morbidit*)).mp. We also screened the reference lists of included studies for possible additional studies to assess eligibility.

### Selection of sources of evidence

Two reviewers (CH and JB) screened the initial studies that were retrieved for eligibility. The first screen was based on the study title and abstract; the next screen used the full text. Any disagreements were resolved by consensus and discussion with a third reviewer if necessary.

The inclusion and exclusion of retrieved studies were reported in a flow diagram according to PRISMA for scoping review reporting guidelines.

### Quality

We report the quality of the evidence as assessed in the original systematic review studies, including the type of tool used.

### Data extraction

We attempted to quantify the risk factors and conditions associated with C-MLTC and report the univariate analysis by conditions and, where reported, results adjusted by non-modifiable risk factors such as age, sex, family history and ethnicity. We extracted data into a template that consisted of the number of studies in the review, the number of participants, and the outcomes for the 18 conditions. One reviewer (IO) extracted the data and checked with a second reviewer (CH). Any disagreements were resolved via consensus.

### Synthesis and dissemination of results

The scoping review is reported according to the PRISMA statement on reporting scoping reviews, 16 and data made available on the Open Science Framework. 17

## Results

### Risk factors for C-MLTC

We found 53 risk factors in the NICE CKS guidance associated with at least one of the 18 Individual Long-Term Conditions (LTCs). Table 1a shows that CKS reports 23 risk factors associated with multimorbidity (two or more LTCs). Of these, 16 risks are associated with C-MLTC (four or more LTCs), of which 11 are modifiable risk factors. Cigarette smoking was the modifiable risk factor associated with most LTCs (n=11), followed by obesity (n=9) and blood pressure (n=8).

Table 1a: Risk factors for Multimorbidity.

CKS reports 30 risk factors associated with only one of the 18 LTCs. See Table 1b: Risk factors for single long-term conditions.

From our initial search of 1482 studies identified from the four different databases, we screened 917 studies. We excluded 765 studies on title and abstract and retrieved 161 reports for full-text screening. Of these, we assessed 61 in detail, excluding 23 as they had no extractable information and three because, on further analysis, they were out of scope (see Figure 1 flow diagram).

We included 35 SRs with 1,019 primary studies (range 4 to 248, median 22 studies). (See the list of included references in Appendix 1). These studies included 115,092,110 participants (range 1,704 to 83,020,812). Web Table 1 reports the systematic reviews’ extractable information. In one review, the number of students and participants was unclear [Roy 2012], 18 and in a further review, the number of participants was unclear [Barami 2012] 19 but not the number of studies. Twenty-five reviews assessed the quality of the studies. Eleven assessment tools were used, with the Newcastle Ottawa tool most frequent (n=9 studies).

Overall, due to inconsistency within the included studies, the results did not allow us to adequately quantify the risk factors and conditions associated with C-MLTC. Seventeen studies quantified the risk of the long-term conditions under study (see Web Table 1). In the reviews we included, no pooled associations were reported for the risk of developing PAD, COPD, Asthma, Anxiety or bipolar affective disorder, osteoporosis, or rheumatoid arthritis. Dementia was the most reported pooled outcome in seven reviews.

When quantifiable results were available, they illustrated the complex interplay long-term conditions have on the development of each other. For example, Huang 2020 showed that COPD patients with heart failure were at significant risk of new-onset AF, whereas other conditions were not.

### Long-term Conditions as Risk Factors for C-MLTC

Table 2 (Long-term Conditions as risk factors for multimorbidity) shows the conditions acting as risk factors for the other 17 conditions. In the table, we removed the association of a condition with itself to give the total number of long-term conditions to which the risk condition contributes. The results show that all but one condition (asthma) is a risk factor for multimorbidity, with 10 conditions associated with C-MLTC. We found that diabetes mellitus is a risk factor for most other conditions (n=10), followed by coronary heart disease, hypertension, and chronic kidney disease (n=8 long-term conditions each). We also found that depression and anxiety are the most other long-term conditions as risk factors (14 and 17, respectively); they contribute little to the risk of developing other conditions.

Counter to the CKS results, Becker 2018 20 reported that anxiety predicts the risk of increased risk of Alzheimer’s disease (HR 1.53, 95% CI 1.16-2.01) and vascular dementia (odds ratio 1.88, 95% CI 1.05-3.36, P < 0.01). Also, Kuring 2020 21 reported a significantly higher risk of developing all-cause dementia (OR 1.91, 1.72-2.12) and AD (OR 1.60,1.29-2.00) in people with previous depression. In Hotzel 2011, 22 anxiety disorders and personality disorders appeared concurrently with chronic depression. In Huang’s 2020a review, 23 CKD plus concomitant depressive symptoms (10 studies) or comorbidity index score (5 studies) increased the risk of anxiety. Khaledi’s 2019 review 24 of 248 studies, including 83 million patients, reported a pooled prevalence of depression among patients with T2DM in the world of 28.0% (95% CI 27-29). Furthermore, Naqvi 2019 25 showed that 47% of rheumatoid arthritis patients had comorbidities. Undiagnosed depression was commonly reported in 58.3% of the patients. However, Steck 2018 highlights that the impact of depression varies depending on the review and the studies included. 26

## Discussion

We found 23 risk factors that contribute to the development of multimorbidity, and 16 are associated with C-MLTC, of which 11 are modifiable risk factors. We also showed that all but one condition (asthma) are risk factors for multimorbidity, and 10 conditions are associated with MLTC. We found that diabetes mellitus is a risk factor for 10 other conditions, followed by coronary heart disease, hypertension, and chronic kidney disease (n=8 long-term conditions each). Our results also show that nearly all long-term conditions act as risks for depression and anxiety. However, due to reporting problems, our results did not allow us to quantify the risk factors and conditions associated with C-MLTC, and depending on the studies chosen, results differed in magnitude and due to a lack of reporting of the temporality we cannot determine the direction of these associations.

Multimorbidity is a relatively new concept compared to single or co-morbid diseases. In 2018, the Lancet published Making More of Multimorbidity as an Emerging Priority, 27 and the Academy of Medical Sciences 28 highlighted that multimorbidity was a priority for global health research. In 2016, NICE guidance on the clinical assessment and management of multimorbidity highlighted evidence for recommendations in NICE guidance on single health conditions, which are regularly drawn from people without multimorbidity and taking fewer prescribed regular medicines. 29

Consequently, numerous areas of contention make multimorbidity complex to study. There has yet to be an international consensus regarding defining and measuring multimorbidity. This makes conducting and interpreting research, comparing findings across populations, and developing guidelines and interventions complex. A review of prevalence studies of multimorbidity found estimates ranging from less than 5% to more than 95%, often due to differences in the operational definition of multimorbidity. 30 A cross-sectional study in Scotland extracted data on 40 morbidities and found that 42% of all patients had one or more morbidities, and 23% were multimorbid. While the prevalence of multimorbidity increased with age, the absolute number of people with multimorbidity was higher in those under 65. 31

While multimorbidity is commonly understood to be the coexistence of multiple health conditions in an individual, and complex multiple long-term conditions (C-MLTC) is the coexistence of four or more health conditions, the exact components are ill-defined. For example, NICE has a more extensive list that constitutes multimorbidity conditions, including physical and mental health conditions such as diabetes or schizophrenia, ongoing conditions such as learning disability, symptom complexes such as frailty or chronic pain, sensory impairment such as sight or hearing loss, and alcohol and substance misuse. A systematic review emphasised the heterogeneity of existing multimorbidity indices. Of the 39 included studies in the review, more than half (59%) had no selection criteria for the conditions included. On average, the studies included 18.5 diseases, ranging between 4 and 102 different conditions, 32 identifying more than 150 different conditions that might account for multimorbidity. However, several conditions, including diabetes mellitus, stroke, COPD, cancer, arthritis, and hypertension, were listed in nearly every study. The review concluded that an important similarity across studies is the focus on diseases with a high prevalence and a severe impact on affected individuals, as this present overview seeks to do.

### Limitations

Our approach has several limitations. First, we found it difficult to locate studies. The term multimorbidity has recently been defined, and the studies we chose to include often did not reflect what was included in many reviews. However, the conditions we focussed on include the most commonly reported and prevalent in the UK general population, in mid-life (45-64 years) and in early old age (64-85 years). 33, 34, 35 Some studies have analysed the interaction of hundreds of conditions. 36 This approach is more comprehensive, but it remains to be seen if this process is generalisable and valuable for clinical practice. Furthermore, we found substantial problems with reporting and a lack of standard definitions and terminology. Inconsistent reporting occurs because most studies are set up to analyse comorbidities and not multimorbidity. It is also unclear whether systematic reviews are the way to study multimorbidity. We do not know the extent to which results can be generalised outside of the country setting by different characteristics such as ethnicity, differing disease definitions and ascertainment of cases. Furthermore, we were unable to assess the interaction of risk factors.

For example, the odds of having peripheral arterial disease increase with higher numbers of risk factors. One risk factor gives a 1.5-fold increase, and three or more gives a 10-fold increase. 37 In addition, NICE CKS results are not backed up by a systematic approach to risk factor identification. They differ from the results of several systematic reviews in identifying risk factors.

### Implications for research

Our findings show the need for consistency in the definitions of long-term conditions and multimorbidity. An agreed glossary of definitions and reporting standards would aid the development of relevant evidence synthesis. A register of population-based studies on multimorbidity and reporting the methods used, the disease studied, and the outcomes of interest may prove a helpful resource. This is particularly important given the study of multimorbidity is in its infancy. There is a need to connect evidence from single diseases and comorbid conditions with the growing problem of multimorbidity and C-MLTC management. However, an attempt to synthesise the evidence on multimorbidity will be labour-intensive. For example, over ten thousand (10 000) systematic reviews on diabetes mellitus are indexed in PubMed. The limitations in the generalisability of findings may mean that results may not transfer to other settings. Therefore, limiting results to country-specific settings may be more coherent when analysing the risks of multimorbidity and C-MLTC.

## Conclusions

Our Scoping review shows that several risks and conditions contribute to the development of multimorbidity and C-MLTC. Anxiety and depression are nearly associated with all long-term conditions. Reporting problems within the systematic reviews and a lack of clear definitions prevented us from adequately quantifying the risk factors and conditions associated with C-MLTC.

## Supporting information

see Figure 1 flow diagram [[supplements/310078_file02.docx]](pending:yes)

Table 1a: Risk factors for Multimorbidity. [[supplements/310078_file03.docx]](pending:yes)

See Table 1b: Risk factors for single long-term conditions. [[supplements/310078_file04.docx]](pending:yes)

Web Table 1 [[supplements/310078_file05.xlsx]](pending:yes)

Table 2 (Long-term Conditions as risk factors for multimorbidity) [[supplements/310078_file06.docx]](pending:yes)

## Data Availability

Data are made available online on the Open Science Framework

[https://osf.io/vte3a/](https://osf.io/vte3a/) 

## Funding

This project is funded by the NIHR Programme Grants for Applied Research Programme (NIHR204406). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

## Competing Interests

CH receives funding support from the NIHR (National Institute for Health Research) School for Primary Care Research Evidence Synthesis Working Group: NIHR SPCR ESWG project 390 and NIHR Program Grant NIHR204406. He is an NHS urgent care GP (full declaration at [www.phc.ox.ac.uk/team/carl-Heneghan](http://www.phc.ox.ac.uk/team/carl-Heneghan)). JPS receives funding from the Wellcome Trust/Royal Society via a Sir Henry Dale Fellowship (ref: 211182/Z/18/Z), the National Institute for Health and Care Research (NIHR) and the British Heart Foundation (refs: PG/21/10341; FS/19/13/34235). This research was funded, in part, by the Wellcome Trust [211182/Z/18/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. JB is a major shareholder in the Trip Database search engine ([www.tripdatabase.com](http://www.tripdatabase.com)) as well as being an employee. RP receives funding support from the NIHR Programme Grants for Applied Research, NIHR Applied Research Collaboration Oxford and Thames Valley and the NIHR Community Healthcare MedTech and in-Vitro Diagnostic Cooperative. AT receives funding support from the NIHR Oxford BRC, NIHR Oxford HealthTech Research Centre and the NIHR-ARC Oxford and Thames Valley. IO, KB and DB have no conflicts to declare.

*   Received July 8, 2024.
*   Revision received July 8, 2024.
*   Accepted July 8, 2024.


*   © 2024, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1.Multimorbidity: Technical Series on Safer Primary Care. Geneva: World Health Organization 2016. Licence: CC BY-NC-SA 3.0 IG [https://apps.who.int/iris/bitstream/handle/10665/252275/9789241511650-eng.pdf;jsessionid=B72C21D47211990535AA47913161BEDE?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/252275/9789241511650-eng.pdf;jsessionid=B72C21D47211990535AA47913161BEDE?sequence=1) (accessed 9 May 2023)
    
    

2.  2.World Health Organization. Factsheet: Non-communicable diseases. [https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases](https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases) (accessed 9 May 2023).
    
    

3.  3.England NHS. NHS England » Multimorbidity – the biggest clinical challenge facing the NHS? [https://www.england.nhs.uk/blog/dawn-moody-david-bramley/](https://www.england.nhs.uk/blog/dawn-moody-david-bramley/) (accessed 9 May 2023).
    
    

4.  4.Leonard A. The theories of Thomas Sydenham (1624-1689). J R Coll Physicians Lond. 1990 Apr;24(2):141–3.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=2191117&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

5.  5.Feinstein A. The pre-therapeutic classification of co-morbidity in chronic disease. J Chron Dis. 1970;23:455–468
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/0021-9681(70)90054-8&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26309916&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1970I667400002&link_type=ISI) 

6.  6.Nunes BP, Flores TR, Mielke GI, Thumé E, Facchini LA. Multimorbidity and mortality in older adults: A systematic review and meta-analysis. Arch Gerontol Geriatr 2016;67:130–8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.archger.2016.07.008&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27500661&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

7.  7.Makovski TT, Schmitz S, Zeegers MP, Stranges S, van den Akker M. Multimorbidity and quality of life: Systematic literature review and meta-analysis. Ageing Res Rev. 2019 Aug;53:100903. doi: 10.1016/j.arr.2019.04.005.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.arr.2019.04.005&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

8.  8.Ong KY, Lee PSS, Lee ES. Patient-centred and not disease-focused: a review of guidelines and multimorbidity. Singapore Med J. 2020 Nov;61(11):584–590. doi: 10.11622/smedj.2019109. Epub 2019 Sep 6. PMID: 31489434; PMCID: PMC8040921.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.11622/smedj.2019109&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31489434&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

9.  9.Stannard S, Berrington A, Paranjothy S et al. A conceptual framework for characterising lifecourse determinants of multiple long-term condition multimorbidity. J Multimorb Comorb. 2023 Sep 3;13:26335565231193951. doi: 10.1177/26335565231193951. PMID: 37674536; PMCID: PMC10478563.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/26335565231193951&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=37674536&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

10. 10.Smith SM, Wallace E, O’Dowd T, Fortin M. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database Syst Rev. 2021 Jan 15;1(1):CD006560. doi: 10.1002/14651858.CD006560.pub4. PMID: 33448337; PMCID: PMC8092473.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/14651858.CD006560.pub4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

11. 11.Moffat, K., Mercer, S.W. Challenges of managing people with multimorbidity in today’s healthcare systems. BMC Fam Pract 16, 129 (2015). doi:10.1186/s12875-015-0344-4
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12875-015-0344-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26462820&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

12. 12.Soley-Bori M, Bisquera A, Ashworth M, Wang Y, Durbaba S, Dodhia H, Fox-Rushby J. Identifying multimorbidity clusters with the highest primary care use: 15 years of evidence from a multi-ethnic metropolitan population. Br J Gen Pract. 2022 Feb 24;72(716):e190–e198. doi: 10.3399/BJGP.2021.0325. PMID: 34782317; PMCID: PMC8597767.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiYmpncCI7czo1OiJyZXNpZCI7czoxMToiNzIvNzE2L2UxOTAiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNC8wNy8wOC8yMDI0LjA3LjA4LjI0MzEwMDc4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

13. 13.Cassell A, Edwards D, Harshfield A, Rhodes K, Brimicombe J, Payne R, Griffin S. The epidemiology of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2018 Apr;68(669):e245–e251. doi: 10.3399/bjgp18X695465. Epub 2018 Mar 12.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiYmpncCI7czo1OiJyZXNpZCI7czoxMToiNjgvNjY5L2UyNDUiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNC8wNy8wOC8yMDI0LjA3LjA4LjI0MzEwMDc4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

14. 14.Prados-Torres A, Calderón-Larrañaga A, Hancco-Saavedra J, Poblador-Plou B, van den Akker M. Multimorbidity patterns: a systematic review. J Clin Epidemiol. 2014 Mar;67(3):254–66. doi: 10.1016/j.jclinepi.2013.09.021.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jclinepi.2013.09.021&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24472295&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

15. 15.Kingston A, Robinson L, Booth H, Knapp M, Jagger C. Projections of multi-morbidity in the
    
    

16. 16.Tricco, AC, Lillie, E, Zarin, W, O’Brien, KK, Colquhoun, H, Levac, D, Moher, D, Peters, MD, Horsley, T, Weeks, L, Hempel, S et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018,169(7):467–473. doi:10.7326/M18-0850.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/M18-0850&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30178033&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

17. 17.Heneghan C, Bennett D, Pidduck N, Spencer EA. (2023, May 3). Complex Multiple long-term conditions - Phenotypes, Trends, and Endpoints (CoMPuTE): Scoping Reviews. Retrieved from [https://osf.io/vte3a/](https://osf.io/vte3a/)
    
    

18. 18.Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012 Oct;142 Suppl:S8–21. doi: 10.1016/S0165-0327(12)70004-6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0165-0327(12)70004-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23062861&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

19. 19.Barami K, Lyon L, Conell C. Type 2 Diabetes Mellitus and Glioblastoma Multiforme-Assessing Risk and Survival: Results of a Large Retrospective Study and Systematic Review of the Literature. World Neurosurg. 2017 Oct;106:300–307. doi: 10.1016/j.wneu.2017.06.164.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.wneu.2017.06.164&link_type=DOI) 

20. 20.Becker E, Orellana Rios CL, Lahmann C, Rücker G, Bauer J, Boeker M. Anxiety as a risk factor of Alzheimer’s disease and vascular dementia. Br J Psychiatry. 2018 Nov;213(5):654–660. doi: 10.1192/bjp.2018.173. Erratum in: Br J Psychiatry. 2019 Mar;214(3):174.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1192/bjp.2018.173&link_type=DOI) 

21. 21.Kuring JK, Mathias JL, Ward L. Risk of Dementia in persons who have previously experienced clinically-significant Depression, Anxiety, or PTSD: A Systematic Review and Meta-Analysis. J Affect Disord. 2020 Sep 1;274:247–261. doi: 10.1016/j.jad.2020.05.020.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jad.2020.05.020&link_type=DOI) 

22. 22.Hölzel L, Härter M, Reese C, Kriston L. Risk factors for chronic depression--a systematic review. J Affect Disord. 2011 Mar;129(1-3):1–13. doi: 10.1016/j.jad.2010.03.025.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jad.2010.03.025&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20488546&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

23. 23.Huang CW, Wee PH, Low LL, Koong YLA, Htay H, Fan Q, Foo WYM, Seng JJB. Prevalence and risk factors for elevated anxiety symptoms and anxiety disorders in chronic kidney disease: A systematic review and meta-analysis. Gen Hosp Psychiatry. 2021 Mar-Apr;69:27–40. doi: 10.1016/j.genhosppsych.2020.12.003.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.genhosppsych.2020.12.003&link_type=DOI) 

24. 24.Khaledi M, Haghighatdoost F, Feizi A, Aminorroaya A. The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol. 2019 Jun;56(6):631–650. doi: 10.1007/s00592-019-01295-9.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00592-019-01295-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

25. 25.Naqvi AA, Hassali MA, Aftab MT. Epidemiology of rheumatoid arthritis, clinical aspects and socio-economic determinants in Pakistani patients: A systematic review and meta-analysis. J Pak Med Assoc. 2019 Mar;69(3):389–398.
    
    

26. 26.Steck N, Cooper C, Orgeta V. Investigation of possible risk factors for depression in Alzheimer’s disease: A systematic review of the evidence. J Affect Disord. 2018 Aug 15;236:149–156. doi: 10.1016/j.jad.2018.04.034.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jad.2018.04.034&link_type=DOI) 

27. 27.The Lancet. Making more of multimorbidity: an emerging priority. Lancet. 2018 Apr 28;391(10131):1637. doi: 10.1016/S0140-6736(18)30941-3. Epub 2018 Apr 26. PMID: 29726322.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(18)30941-3&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29726322&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

28. 28.Academy of Medical Sciences; 2018. Multimorbidity: a priority for global health research. [https://acmedsci.ac.uk/policy/policy-projects/multimorbidity](https://acmedsci.ac.uk/policy/policy-projects/multimorbidity)
    
    

29. 29.Multimorbidity: clinical assessment and management. NICE guideline [NG56]Published: 21 September 2016. [https://www.nice.org.uk/guidance/ng56](https://www.nice.org.uk/guidance/ng56)
    
    

30. 30.Defining and measuring multimorbidity: a systematic review of systematic reviews European Journal of Public Health, Volume 29, Issue 1, February 2019, Pages 182–189, doi:10.1093/eurpub/cky098
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/eurpub/cky098&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29878097&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

31. 31.Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012 Jul 7;380(9836):37–43. doi: 10.1016/S0140-6736(12)60240-2.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(12)60240-2&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22579043&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000306115900031&link_type=ISI) 

32. 32.Diederichs C, Berger K, Bartels DB. The measurement of multiple chronic diseases--a systematic review on existing multimorbidity indices. J Gerontol A Biol Sci Med Sci. 2011 Mar;66(3):301–11. doi: 10.1093/gerona/glq208.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/gerona/glq208&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21112963&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000288415800007&link_type=ISI) 

33. 33.Cassell A, Edwards D, Harshfield A, Rhodes K, Brimicombe J, Payne R, et al. The epidemiology of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract
    
    

34. 34.Prados-Torres A, Calderón-Larrañaga A, Hancco-Saavedra J, Poblador-Plou B, van den Akker M. Multimorbidity patterns: a systematic review. J Clin Epidemiol. 2014 Mar;67(3):254–66. doi: 10.1016/j.jclinepi.2013.09.021. PMID: 24472295.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jclinepi.2013.09.021&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24472295&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

35. 35.Kingston A, Robinson L, Booth H, Knapp M, Jagger C; MODEM project. Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model. Age Ageing. 2018 May 1;47(3):374–380. doi: 10.1093/ageing/afx201. PMID: 29370339; PMCID: PMC5920286.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ageing/afx201&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29370339&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F08%2F2024.07.08.24310078.atom) 

36. 36.Kuan V, Denaxas S, Patalay P, Nitsch D, Mathur R, Gonzalez-Izquierdo A, Sofat R, Partridge L, Roberts A, Wong ICK, Hingorani M, Chaturvedi N, Hemingway H, Hingorani AD; Multimorbidity Mechanism and Therapeutic Research Collaborative (MMTRC). Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study. Lancet Digit Health. 2023 Jan;5(1):e16–e27. doi: 10.1016/S2589-7500(22)00187-X. Epub 2022 Nov 29.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S2589-7500(22)00187-X&link_type=DOI) 

37. 37.Firnhaber JM, Powell CS. Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment. Am Fam Physician. 2019 Mar 15;99(6):362–369. Erratum in: Am Fam Physician. 2019 Jul 15;100(2):74.